Cargando…

A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome

BACKGROUND AND PURPOSE: Irritable bowel syndrome (IBS) is a disease that shows its impacts on many populations worldwide. It is known as a functional disorder of the gastrointestinal tract followed by diarrhea and fecal inconsistency. Due to the lack of treatment in the allopathic medicine system fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Heydari, Parisa, Ghanadian, Mustafa, Asghari, Gholamreza, Azimi, Maryam, Babaeian, Mahmoud, Adibi, Peyman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951779/
https://www.ncbi.nlm.nih.gov/pubmed/36846732
http://dx.doi.org/10.4103/1735-5362.363599
_version_ 1784893465215107072
author Heydari, Parisa
Ghanadian, Mustafa
Asghari, Gholamreza
Azimi, Maryam
Babaeian, Mahmoud
Adibi, Peyman
author_facet Heydari, Parisa
Ghanadian, Mustafa
Asghari, Gholamreza
Azimi, Maryam
Babaeian, Mahmoud
Adibi, Peyman
author_sort Heydari, Parisa
collection PubMed
description BACKGROUND AND PURPOSE: Irritable bowel syndrome (IBS) is a disease that shows its impacts on many populations worldwide. It is known as a functional disorder of the gastrointestinal tract followed by diarrhea and fecal inconsistency. Due to the lack of treatment in the allopathic medicine system for IBS, people in the western world use different herbs as alternative medicine. In the present study, we evaluated the dried extract of Dracocephalum kotschyi against IBS. EXPERIMENTAL APPROACH: In a randomized, double-blinded, placebo-controlled clinical trial, 76 diarrhea-predominant IBS patients were randomly assigned to two equal groups: the control group (given the placebo capsule containing 250 mg of dibasic calcium phosphate) and the treatment groups (given the capsule containing 75 mg of the dry extract of D. kotschyi and 175 mg of dibasic calcium phosphate as filler). The study was conducted based on Rome III criteria. We studied symptoms included in Rome III criteria and divided the study into the duration of drug administration and four weeks after drug administration. These groups were compared with those of the control group. FINDINGS/RESULTS: Significant improvements were found in the quality of life, temperament, and IBS symptoms throughout the treatment duration. Quality of life, temperature, and IBS symptoms were slightly decreased in the treatment group 4 weeks after stopping the treatment. While concluding the study, we found D. kotschyi effective against IBS. CONCLUSION AND IMPLICATIONS: Whole extract of D. kotschyi modulated symptoms of IBS patients and improved their quality of life.
format Online
Article
Text
id pubmed-9951779
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-99517792023-02-25 A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome Heydari, Parisa Ghanadian, Mustafa Asghari, Gholamreza Azimi, Maryam Babaeian, Mahmoud Adibi, Peyman Res Pharm Sci Original Article BACKGROUND AND PURPOSE: Irritable bowel syndrome (IBS) is a disease that shows its impacts on many populations worldwide. It is known as a functional disorder of the gastrointestinal tract followed by diarrhea and fecal inconsistency. Due to the lack of treatment in the allopathic medicine system for IBS, people in the western world use different herbs as alternative medicine. In the present study, we evaluated the dried extract of Dracocephalum kotschyi against IBS. EXPERIMENTAL APPROACH: In a randomized, double-blinded, placebo-controlled clinical trial, 76 diarrhea-predominant IBS patients were randomly assigned to two equal groups: the control group (given the placebo capsule containing 250 mg of dibasic calcium phosphate) and the treatment groups (given the capsule containing 75 mg of the dry extract of D. kotschyi and 175 mg of dibasic calcium phosphate as filler). The study was conducted based on Rome III criteria. We studied symptoms included in Rome III criteria and divided the study into the duration of drug administration and four weeks after drug administration. These groups were compared with those of the control group. FINDINGS/RESULTS: Significant improvements were found in the quality of life, temperament, and IBS symptoms throughout the treatment duration. Quality of life, temperature, and IBS symptoms were slightly decreased in the treatment group 4 weeks after stopping the treatment. While concluding the study, we found D. kotschyi effective against IBS. CONCLUSION AND IMPLICATIONS: Whole extract of D. kotschyi modulated symptoms of IBS patients and improved their quality of life. Wolters Kluwer - Medknow 2022-12-24 /pmc/articles/PMC9951779/ /pubmed/36846732 http://dx.doi.org/10.4103/1735-5362.363599 Text en Copyright: © 2022 Research in Pharmaceutical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Heydari, Parisa
Ghanadian, Mustafa
Asghari, Gholamreza
Azimi, Maryam
Babaeian, Mahmoud
Adibi, Peyman
A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome
title A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome
title_full A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome
title_fullStr A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome
title_full_unstemmed A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome
title_short A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome
title_sort double-blind randomized clinical trial of dracocephalum kotschyi boiss. in the patients with diarrhea-predominant irritable bowel syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951779/
https://www.ncbi.nlm.nih.gov/pubmed/36846732
http://dx.doi.org/10.4103/1735-5362.363599
work_keys_str_mv AT heydariparisa adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT ghanadianmustafa adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT asgharigholamreza adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT azimimaryam adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT babaeianmahmoud adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT adibipeyman adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT heydariparisa doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT ghanadianmustafa doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT asgharigholamreza doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT azimimaryam doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT babaeianmahmoud doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome
AT adibipeyman doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome